ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.22% | 10.22% | 90.04% | 794.47% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.35% | 38.83% | 113.97% | 620.60% | -- |
| Operating Income | 0.35% | -38.83% | -113.97% | -620.60% | -- |
| Income Before Tax | 81.76% | 80.25% | 77.92% | -3,424.69% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 81.76% | 80.25% | 77.92% | -3,424.69% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.76% | 80.25% | 77.92% | -3,424.69% | -- |
| EBIT | 0.35% | -38.83% | -113.97% | -620.60% | -- |
| EBITDA | 0.44% | -38.81% | -113.97% | -620.60% | -- |
| EPS Basic | 88.51% | 87.61% | 83.78% | -1,789.94% | -- |
| Normalized Basic EPS | 30.93% | 15.63% | 173.36% | -213.21% | -- |
| EPS Diluted | 87.87% | 86.97% | 81.79% | -1,255.37% | -- |
| Normalized Diluted EPS | 30.93% | 15.63% | 173.36% | -213.21% | -- |
| Average Basic Shares Outstanding | 62.67% | 112.63% | 91.42% | 115.63% | -- |
| Average Diluted Shares Outstanding | 62.67% | 112.63% | 91.42% | 115.63% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
